ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0207

Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital

Carmen Álvarez-Reguera1, Jorge Javier Gaitán-Valdizán1, Raúl fernández-ramón1, Rosalia Demetrio-Pablo1, José Luis Martin-Varillas2, Lara Sánchez-Bilbao1, David Martinez-Lopez1, Iñigo Gonzalez-Mazon3, Miguel Ángel gonzalez-Gay4 and Ricardo Blanco5, 1Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Sierrallana, Torrelavega, Spain, 3H. U. Marques de Valdecilla, Santander, Spain, 4Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 5Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2021

Keywords: , ,

Session Information

Date: Saturday, November 6, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Ocular involvement is a relatively frequent and potentially severe complication of sarcoidosis. Oral corticosteroids (OCS) are the first-line treatment. Conventional immunosuppressive agents (cIS) and biological therapy (BT) can be used in refractory cases.

The aim of this study was to evaluate the treatment and visual outcomes of a cohort of patients diagnosed with ocular sarcoidosis.

Methods: Study of a large cohort (n=384) of all consecutive patients diagnosed with sarcoidosis from January 1, 1999 to December 31, 2019 at a single University Hospital. Finally, 344 patients were included according the ATS/ERS/WASOG criteria l Different ocular manifestations and the following systemic treatments were assessed: a) OCS, b) cIS), c) monoclonal TNF inhibitors, d) Etanercept (ETN), e) Tocilizumab (TCZ). Best Corrected Visual Acuity (BCVA) according to different systemic treatments was compared at diagnosis and after one year of follow-up (Kruskall Wallis test).

Results: 344 patients were reviewed. From these, 65 (18.9%) presented ocular manifestations as uveitis (83.1%), orbital lesions (7.7%), retinal vasculitis (6.2%), dry eye (6.2%) and scleritis (1.5%). All of them received systemic treatment. BT was particularly used in patients with retinal vasculitis (100%), panuveitis (75%) and orbital lesions (40%). Systemic treatment and BCVA outcome according to ocular manifestations are shown in table. Median BCVA at onset and after one year was 0.6 [interquartile range (IQR) 0.3-0.8] and 0.9 [0.6-1], respectively. No statistically significant differences were observed between systemic treatments in BCVA of patients with uveitis after 1 year of follow-up (Figure).

Conclusion: Panuveitis, intermediate uveitis and orbital lesions, require a more aggressive treatment than other manifestations of ocular sarcoidosis. In uveitis, an important improvement in BCVA after 1 year of follow-up was observed regardless of the type of treatment used.

Disclosures: C. Álvarez-Reguera, None; J. Gaitán-Valdizán, None; R. fernández-ramón, None; R. Demetrio-Pablo, None; J. Martin-Varillas, None; L. Sánchez-Bilbao, None; D. Martinez-Lopez, None; I. Gonzalez-Mazon, None; M. gonzalez-Gay, None; R. Blanco, Brystol Myers Squibb, 6.

To cite this abstract in AMA style:

Álvarez-Reguera C, Gaitán-Valdizán J, fernández-ramón R, Demetrio-Pablo R, Martin-Varillas J, Sánchez-Bilbao L, Martinez-Lopez D, Gonzalez-Mazon I, gonzalez-Gay M, Blanco R. Treatment of Ocular Sarcoidosis: Study of 65 Patients of a Series of 384 Patients from a Single University Hospital [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/treatment-of-ocular-sarcoidosis-study-of-65-patients-of-a-series-of-384-patients-from-a-single-university-hospital/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-of-ocular-sarcoidosis-study-of-65-patients-of-a-series-of-384-patients-from-a-single-university-hospital/